Literature DB >> 33085811

Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy.

Markus Kinner1, Christian Prehn1, Ruth Schneider1, Christoph Schroeder1, Eva Kolb1, Ralf Gold1, Robert Hoepner1,2, Andew Chan1,2.   

Abstract

BACKGROUND AND
PURPOSE: Progressive multifocal leukoencephalopathy (PML), an opportunistic infection of the central nervous system from the John Cunningham virus (JCV), is a side effect of natalizumab (NTZ) treatment for relapsing-remitting multiple sclerosis (RRMS), potentially leading to a substantial increase of physical and mental disability. Nevertheless, data of neuropsychological impairment during the NTZ-PML disease course are missing. Our objective was to evaluate the neuropsychological disease course of NTZ-PML patients and to compare neuropsychological deficits of NTZ-PML patients with two different non-PML multiple sclerosis (MS) cohorts.
METHODS: Neuropsychological examinations of 28 NTZ-PML patients performed during different phases of the disease ([i] at PML diagnosis, [ii] during immune reconstitution inflammatory syndrome [IRIS], and [iii] post-IRIS/PML) were retrospectively analyzed and compared to those of NTZ-treated RRMS or secondary progressive MS patients with and without immunotherapy.
RESULTS: Compared to controls, NTZ-PML patients performed worse in neuropsychological examinations during all stages of disease, mainly affecting visuospatial ability and working memory. Furthermore, failure to eliminate the JCV from the central nervous system was associated with a progredient decline of cognition, especially working memory.
CONCLUSIONS: Working memory and visuospatial abilities are the core neuropsychological deficits of NTZ-PML patients in long-term follow-up. Our findings should be implemented in neurorehabilitation strategies.
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Entities:  

Keywords:  PML; Tysabri; cognition; natalizumab; progressive multifocal leukoencephalopathy; psychiatry; relapsing-remitting multiple sclerosis

Year:  2020        PMID: 33085811     DOI: 10.1111/ene.14604

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  1 in total

1.  Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy.

Authors:  Viviana Lo Buono; Giangaetano D'Aleo; Simona Cammaroto; Maria Cristina De Cola; Francesca Palmese; Chiara Smorto; Silvia Marino; Giuseppe Venuti; Edoardo Sessa; Carmela Rifici; Francesco Corallo
Journal:  Medicina (Kaunas)       Date:  2022-04-17       Impact factor: 2.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.